Vaxart Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Source: seekingalpha
- Strengthened Partnership: Vaxart's collaboration with Dynavax includes a $25 million upfront payment and a $5 million equity investment, with a total potential value of up to $700 million, showcasing the robust potential of its oral vaccine platform and expected to drive future revenue growth.
- Significant Revenue Growth: Vaxart reported revenue of $237.3 million for 2025, a substantial increase from $28.7 million in 2024, primarily attributed to revenue recognition from BARDA contracts and the Dynavax collaboration agreement, reflecting enhanced competitiveness in the vaccine market.
- Operational Cost Optimization: The company is reducing operating expenses through a lease termination agreement effective May 2026, allowing Vaxart to focus more financial resources on lead programs, thereby enhancing its financial flexibility.
- Clinical Trial Progress: The Phase IIb trial of the oral COVID-19 vaccine is ongoing, with top-line data from the 400-participant safety cohort expected in early Q2 2026; although the timeline has shifted, it still demonstrates the company's continued commitment to vaccine development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
